Bad Medicine – Editorial – Guardian UK

Bad Medicine – Editorial – Guardian UK

Sat, 12 Jun 2004

New York State Attorney General, Eliot Spitzer, is being recognized as a hero on both sides of the Atlantic. That’s because, unlike FDA officials, he knows how to use a “smoking gun” to affect change in corporate practices to protect the public health!

An editorial in the Guardian (UK) notes that the significance of Sptizer’s lawsuit against GlaxoSmithKline, goes far beyond the modest fine it seeks. This suit charges the company–and by extension the pharmaceutical industry–with fraudulent marketing. Spitzer’s suit is a quantum leap toward redirecting the marketing practices for prescription drugs.

“..in choosing to charge the company with fraud, the New York suit may change the way pharmaceutical companies market and sell their drugs.”

Spitzer’s probe may help restore the integrity of medicine by exposing the physicians who collaborated in industry’s fraudulent practices. The integrity of medicine hinges on disengagement from the corrupting influence of pharmaceutical $$ incentives.

See: “Smoking gun” internal 1998 Glaxo memo:
http://www.ahrp.org/risks/SSRI0204/GSKpaxil/pg1.html

Contact: Vera Hassner Sharav
Tel: 212-595-8974

http://www.guardian.co.uk/leaders/story/0,3604,1237013,00.html
Bad medicine
Leader
Saturday June 12, 2004
The Guardian

The decision by New York’s attorney general to sue GlaxoSmithKline for “persistent and repeated fraud” represents a more dramatic challenge to the major pharmaceutical makers than first realised. Distracted by the modesty of the lawsuit’s demands – a fine equivalent to the profits Glaxo made from sales of its antidepressant Paxil (called Seroxat in the UK) to children – there is temptation to dismiss the case as small beer. Glaxo’s sales of Paxil to under-18s are estimated to be around £140m, a piffling fine for a company worth £67bn. If that were all Glaxo had to worry about, then this would be an embarrassing episode. But in choosing to charge the company with fraud, the New York suit may change the way pharmaceutical companies market and sell their drugs. At the heart of the suit are allegations that Glaxo deliberately downplayed several studies that showed Paxil to be ineffective and liable to provoke suicidal impulses. Eliot Spitzer has a smoking gun in the form of memos from Glaxo, including one which says the company wanted to “manage the dissemination of these data in order to minimise any potential negative commercial impact”.

Glaxo rejects the suit, and says it had not covered up anything. Yet Mr Spitzer argues the company is guilty of fraud if it fails to inform doctors of the full spectrum of results for a drug. There are some recent cases that should encourage the New York suit: Pfizer, the world’s largest drug manufacturer, recently paid a £240m fine for promoting a product with no benefits. Glaxo itself is under investigation in Italy for an estimated £150m worth of gifts to doctors there.

Mr Spitzer has an impressive record in calling Wall Street’s banks to account for their misdeeds, and changing their less wholesome practices. His attempt to clean up “big pharma” is just as worthy of support, all the more because the UK sorely lacks an equivalent to Mr Spitzer and his wide-ranging powers. The drug industry must not be allowed to act like West End theatre advertisers, cherry-picking the reviews that suit them. The stakes are far too high.

FAIR USE NOTICE: This may contain copyrighted (© ) material the use of which has not always been specifically authorized by the copyright owner. Such material is made available for educational purposes, to advance understanding of human rights, democracy, scientific, moral, ethical, and social justice issues, etc. It is believed that this constitutes a ‘fair use’ of any such copyrighted material as provided for in Title 17 U.S.C. section 107 of the US Copyright Law. This material is distributed without profit.